The Supreme Court sided with government regulators in an important case involving the pharmaceutical industry and patent law. At issue were contracts between "brand-name" pharmaceutical companies and "generic" producers in which the brand-name company paid the generic not to compete. The court said the Federal Trade Commission could challenge such contracts.
The pendulum of this year's NBA finals has swung again. The first win in the series went to the San Antonio Spurs, the next to the Miami heat, then Spurs, then Heat. And last night, the Spurs won game five. That puts them one game away from winning their fifth NBA title, all with Gregg Popovich as their coach and all with Tim Duncan as one of their key players. But the series reverts to Miami tomorrow night. NPR's Mike Pesca will be there, and he joins us now. Hi, Mike.
When the maker of a brand-name drug pays a maker of generic drugs to not produce a lower-priced version of their product, the Federal Trade Commission can challenge the arrangement on antitrust grounds, the Supreme Court ruled Monday. The ruling may end the era of what regulators call "pay-for-delay" deals.
The justices voted 5-3 to allow a case to go forward in which the FTC is challenging one of many such deals. Several companies are involved in the case, including Solvay Pharmaceuticals, maker of AndroGel, and generic-drug maker Actavis.
Ever since Iran's 1979 Islamic Revolution, the U.S. has been in search of moderate Iranian leaders who could steer the country away from its hostile standoff with America.
To cite one famous example, President Ronald Reagan's administration secretly sold weapons to Iran in the mid-1980s in the belief it could work with the country's "moderate" elements even as Iran remained under the control of revolutionary leader Ayatollah Ruhollah Khomeini.
We've written before about the wealth gap between whites and people of color — a divide that's only grown wider over the past half decade. And since so much of Americans' household wealth is wrapped up in homes, a significant amount of that wealth gap has been chalked up to an array of barriers to homeownership for people of color.
Few citizens are more honored than military veterans, and there's particular reverence for those who defeated the Nazis in World War II. Like any war, however, World War II was complicated and traumatic for those on the ground, and not a few deserted from the front lines.